Opportunity Information: Apply for RFA DD 11 006
Apply for RFA DD 11 006
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "Muscular Dystrophy Surveillance Tracking and Research Network MD STARnet Feasibility of Expansion to other Muscular Dystrophies" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.283 Centers for Disease Control and PreventionInvestigations and Technical Assistance.
- This funding opportunity was created on Dec 16, 2010 and posted on Dec 16, 2010.
- Applicants must submit their applications by Mar 24, 2011 On time submission requires that electronic applications be error free and made available to CDC for processing from eRA Commons on or before the deadline date. Applications must be submitted to and validated successfully by Grants.gov/eRA Commons no later than 500 PM Eastern Time. Note HHS/CDC grant submission procedures do not provide a period of time beyond the application due date to correct any error or warning notices of noncompliance with application instructions that are identified by Grants.gov or eRA systems (i.e., error correction window).. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $450,000.00 in funding.
- The number of recipients for this funding is limited to 5 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Only organizations operating as established MD STARnet sites under RFA DD 06 002 or DD 08 002 are eligible to submit an application under this FOA. These eligible sites include 1. University of Arizona, College of Medicine, 2. Colorado Department of Public Health and Environment, 3. University of Iowa, College of Medicine, 4. New York State Department of Health, and 5. Hawaii Department of Health. Existing MD STARnet sites have an established population based Duchenne/Becker muscular dystrophy surveillance system utilizing a unique protocol and methods to collect longitudinal data on individuals with DBMD, and provide the basis for this expansion demonstration effort. Limiting eligibility to these sites enables the continuation of longitudinal data collection on over 700 individuals with DBMD and for efficient expansion of data collection to other muscular dystrophies.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Muscular Dystrophy Surveillance, Tracking and Research Network (MD STARnet) Feasibility of Expansion to other Muscular Dystrophies grant opportunity (Funding Opportunity Number RFA DD 11 006) was a Centers for Disease Control and Prevention (CDC) discretionary funding announcement issued as a cooperative agreement (UO1) in the health category. Its central purpose was to build on the existing MD STARnet public health surveillance infrastructure, which had already been established to track Duchenne and Becker muscular dystrophy (DBMD), and to test and support the modification and expansion of that system so it could better characterize the broader population of people living with muscular dystrophies. The long-term public health goal stated in the announcement was to improve access to care and ultimately improve health outcomes for individuals with muscular dystrophies by strengthening the evidence base on who is affected, how care is delivered over time, and what needs exist across settings.
The FOA was structured in two parts, described as Component A (Core) and Component B (Enhanced Activities). Component A was the required core work and focused on expanding and adapting MD STARnet methods so the network could move beyond DBMD and begin addressing other muscular dystrophies. In practical terms, this meant continuing the established population-based, longitudinal surveillance approach while modifying protocols and data collection processes so that additional muscular dystrophy conditions could be captured in a consistent, comparable way across participating sites. Because MD STARnet already had a unique protocol and mature methods for identifying cases and gathering follow-up information over time, the expansion effort was positioned as a feasibility and demonstration activity rather than building a new surveillance system from scratch.
Component B was optional and could be requested only by applicants who were applying for the Component A core. These enhanced activities were designed to support and strengthen ongoing MD STARnet operations at a network level. The announcement listed four types of enhanced work that could be proposed: (1) a Data Coordinating Center (DCC) function, which typically involves centralized data management, standardization, integration across sites, and analytic support; (2) abstractor training and quality assurance/quality control activities, aimed at ensuring that medical record abstraction and case ascertainment are done consistently and accurately across participating locations; (3) a national coordinating center role, supporting cross-site coordination, shared procedures, communications, and broader network functioning; and (4) a Georgia healthcare transitions interview activity, suggesting a focused effort to understand transitions in care (for example, from pediatric to adult systems) through interviews conducted in Georgia. In combination, Component B options emphasized data quality, comparability, coordination, and targeted supplemental research tied to care transitions.
Eligibility was deliberately narrow. Only organizations already operating as established MD STARnet sites under prior CDC awards (RFA DD 06 002 or DD 08 002) were permitted to apply. The eligible applicants were the University of Arizona College of Medicine, Colorado Department of Public Health and Environment, University of Iowa College of Medicine, New York State Department of Health, and Hawaii Department of Health. The rationale given was that these sites already maintained a functioning, population-based DBMD surveillance system using standardized MD STARnet methods and were actively collecting longitudinal data on more than 700 individuals with DBMD. Restricting eligibility to these experienced sites allowed CDC to preserve continuity in the existing DBMD dataset while efficiently piloting and scaling expansion to additional muscular dystrophy types without losing consistency in case definitions, abstraction practices, and follow-up procedures.
From an awards and funding perspective, CDC anticipated making up to five awards, aligning with the five eligible MD STARnet sites. The stated award ceiling was $450,000, with no cost sharing or matching requirement. The CFDA number associated with the opportunity was 93.283 (CDC Investigations and Technical Assistance). The opportunity was posted on December 16, 2010, with an original and current closing date of March 24, 2011, and it was later archived on April 23, 2011. Applications were required to be submitted electronically through Grants.gov and validated in eRA Commons by 5:00 PM Eastern Time on the due date, with the notable warning that CDC/HHS procedures did not provide an error-correction window after the deadline; submissions needed to be error-free and fully validated by the cutoff time to be considered on time.
Overall, this FOA represented a targeted investment by CDC in strengthening a proven, population-based surveillance network for muscular dystrophy by maintaining ongoing DBMD longitudinal tracking while methodically extending MD STARnet capacity to other muscular dystrophies. By combining required core expansion work with optional network-level enhancements focused on coordination, training, and quality, the announcement aimed to increase the usefulness, reliability, and reach of MD STARnet data so that public health and clinical stakeholders could better understand the muscular dystrophy population and use that knowledge to improve care access and health outcomes. For technical assistance, the announcement directed applicants to CDC’s Procurement and Grants Office Technical Information Management Section (TIMS) via phone at 770-488-2700.
Frequently Asked Questions (FAQs)
What is the name of this funding opportunity?
The opportunity is titled the "Muscular Dystrophy Surveillance, Tracking and Research Network (MD STARnet) Feasibility of Expansion to other Muscular Dystrophies" grant opportunity.
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is RFA DD 11 006.
Which federal agency issued this announcement?
The announcement was issued by the Centers for Disease Control and Prevention (CDC).
What type of award mechanism is used?
This was a CDC discretionary funding announcement issued as a cooperative agreement (UO1).
What is the overall purpose of the FOA?
The central purpose was to build on the existing MD STARnet public health surveillance infrastructure (originally established to track Duchenne and Becker muscular dystrophy, DBMD) and to test, support, and demonstrate modifications needed to expand the system so it could better characterize the broader population of people living with muscular dystrophies.
What long-term public health goal did CDC describe for this work?
The long-term goal stated in the announcement was to improve access to care and ultimately improve health outcomes for individuals with muscular dystrophies by strengthening the evidence base on who is affected, how care is delivered over time, and what needs exist across settings.
What is MD STARnet already designed to do?
MD STARnet already had established methods and a unique protocol for population-based, longitudinal surveillance to identify cases and gather follow-up information over time for individuals with DBMD.
How is the FOA structured?
The FOA was structured in two parts: Component A (Core) and Component B (Enhanced Activities).
What is Component A (Core)?
Component A was the required core work. It focused on expanding and adapting MD STARnet methods so the network could move beyond DBMD and begin addressing other muscular dystrophies, while continuing the established population-based, longitudinal surveillance approach.
What does the Component A expansion involve in practical terms?
In practical terms, Component A involved modifying protocols and data collection processes so that additional muscular dystrophy conditions could be captured in a consistent, comparable way across participating sites, while maintaining ongoing DBMD longitudinal tracking.
Is the expansion intended to create a brand-new surveillance system?
No. The expansion effort was positioned as a feasibility and demonstration activity that builds on a mature, existing surveillance system rather than creating a new system from scratch.
What is Component B (Enhanced Activities)?
Component B consisted of optional enhanced activities intended to support and strengthen ongoing MD STARnet operations at a network level.
Can applicants apply for Component B without applying for Component A?
No. Component B could be requested only by applicants who were applying for the Component A core.
What enhanced activities were listed as options under Component B?
The announcement listed four types of enhanced work that could be proposed: (1) a Data Coordinating Center (DCC) function, (2) abstractor training and quality assurance/quality control (QA/QC) activities, (3) a national coordinating center role, and (4) a Georgia healthcare transitions interview activity.
What is meant by a Data Coordinating Center (DCC) function in this FOA?
The FOA described the DCC function as typically involving centralized data management, standardization, integration across sites, and analytic support.
What is the purpose of abstractor training and QA/QC under Component B?
Those activities were aimed at ensuring medical record abstraction and case ascertainment are conducted consistently and accurately across participating locations.
What is the national coordinating center role intended to support?
It is intended to support cross-site coordination, shared procedures, communications, and broader network functioning.
What is the Georgia healthcare transitions interview activity?
It suggests a focused effort to understand transitions in care (for example, from pediatric to adult systems) through interviews conducted in Georgia.
Who was eligible to apply?
Eligibility was restricted to organizations already operating as established MD STARnet sites under prior CDC awards (RFA DD 06 002 or DD 08 002).
Which specific organizations were eligible applicants?
The eligible applicants were: University of Arizona College of Medicine; Colorado Department of Public Health and Environment; University of Iowa College of Medicine; New York State Department of Health; and Hawaii Department of Health.
Why was eligibility limited to these organizations?
The rationale provided was that these sites already maintained a functioning, population-based DBMD surveillance system using standardized MD STARnet methods and were actively collecting longitudinal data on more than 700 individuals with DBMD. Restricting eligibility preserved continuity in the existing DBMD dataset and allowed efficient piloting and scaling to other muscular dystrophy types without losing consistency in methods and follow-up procedures.
How many awards did CDC expect to make?
CDC anticipated making up to five awards, aligning with the five eligible MD STARnet sites.
What was the maximum award amount (award ceiling)?
The stated award ceiling was $450,000.
Was cost sharing or matching required?
No. The opportunity stated that there was no cost sharing or matching requirement.
What is the CFDA number associated with this opportunity?
The CFDA number associated with the opportunity was 93.283 (CDC Investigations and Technical Assistance).
What category was this opportunity listed under?
It was issued in the health category.
When was the opportunity posted?
The opportunity was posted on December 16, 2010.
What was the application closing date?
The original and current closing date was March 24, 2011.
When was the opportunity archived?
It was archived on April 23, 2011.
How were applications required to be submitted?
Applications were required to be submitted electronically through Grants.gov.
Was any additional electronic validation required beyond Grants.gov submission?
Yes. Applications also needed to be validated in eRA Commons.
What was the submission deadline time zone and cutoff time?
Applications needed to be submitted and validated by 5:00 PM Eastern Time on the due date.
Was there an error-correction window after the deadline?
No. The announcement specifically warned that CDC/HHS procedures did not provide an error-correction window after the deadline. Submissions had to be error-free and fully validated by the cutoff time to be considered on time.
What types of outcomes was the FOA trying to improve through better surveillance data?
The FOA emphasized improving the usefulness, reliability, and reach of MD STARnet data so public health and clinical stakeholders could better understand who is affected, how care is delivered over time, and what needs exist across settings, with the long-term aim of improving access to care and health outcomes.
Who was listed as a technical assistance contact?
For technical assistance, the announcement directed applicants to CDC's Procurement and Grants Office Technical Information Management Section (TIMS).
What phone number was provided for technical assistance?
The phone number provided was 770-488-2700.
Browse more opportunities from the same category: Health
Next opportunity: Ethics Education in Science and Engineering
Previous opportunity: FY 2011 Vehicle Technologies Program Wide Funding Opportunity Announcement
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DD 11 006
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DD 11 006) also looked into and applied for these:
| Funding Opportunity |
|---|
| Limited Competition for the Renewal of the National Cell Repository for Alzheimers Disease (NCRAD) (U24) Apply for PAR 11 080 Funding Number: PAR 11 080 Agency: National Institutes of Health Category: Health Funding Amount: $675,000 |
| Expanding Maternal and Neonatal Survival (EMAS) Apply for RFA 497 11 000002 Funding Number: RFA 497 11 000002 Agency: Indonesia USAID Jakarta Category: Health Funding Amount: $55,000,000 |
| HIV Prevention with Youth and Adults Program in Lesotho Apply for 674 11 0004 Funding Number: 674 11 0004 Agency: South Africa USAID Pretoria Category: Health Funding Amount: $17,000,000 |
| Clinical Sequencing Exploratory Research (U01) Apply for RFA HG 10 017 Funding Number: RFA HG 10 017 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| Development of a Preliminary Evidence Base to Inform Decision making about Returning Research Results to Participants in Genomic Studies (R01) Apply for RFA HG 11 003 Funding Number: RFA HG 11 003 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Ethical, Legal, and Social Implications of Returning Research Results to Genomic Research Participants (R21) Apply for RFA HG 11 004 Funding Number: RFA HG 11 004 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Long Term MCH Training LEND Apply for HRSA 11 036 Funding Number: HRSA 11 036 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Disparities in Perinatal Health Border, Alaska and Hawaii Apply for HRSA 11 018 Funding Number: HRSA 11 018 Agency: Health Resources and Services Administration Category: Health Funding Amount: $750,000 |
| Improving Access to Hearing Health Care (STTR) R41/R42 Apply for RFA DC 12 002 Funding Number: RFA DC 12 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Improving Access to Hearing Health Care (SBIR) R43/R44 Apply for RFA DC 12 001 Funding Number: RFA DC 12 001 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| Ability of Individual and Integrated Tick Management (ITM) Technologies to Reduce the Entomological Risk of Lyme Disease Apply for RFA CK 11 005 Funding Number: RFA CK 11 005 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $300,000 |
| Combining Subjective and Objective Methods for Quantifying Contact Rates and Mixing Pattern in School Aged Children Apply for RFA CK 11 006 Funding Number: RFA CK 11 006 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Pathophysiology and Clinical Studies of Osteonecrosis of the Jaw (R21) Apply for PAR 11 083 Funding Number: PAR 11 083 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Pathophysiology and Clinical Studies of Osteonecrosis of the Jaw (R01) Apply for PAR 11 082 Funding Number: PAR 11 082 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| National Spina Bifida Registry Longitudinal Data Collection and Evaluation (U01) Apply for RFA DD 11 005 Funding Number: RFA DD 11 005 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $50,000 |
| NIAID Science Education Awards (R25) Apply for PAR 11 086 Funding Number: PAR 11 086 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Georgia Tuberculosis Prevention Project Apply for RFA 114 11 000001 Funding Number: RFA 114 11 000001 Agency: Georgia USAID Tbilisi Category: Health Funding Amount: $4,450,000 |
| Studies at the Animal Human Interface of Influenza and Other Zoonotic Diseases in Vietnam Apply for RFA IP 11 005 Funding Number: RFA IP 11 005 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $400,000 |
| Influenza and Other Respiratory Diseases in Southern Hemisphere Apply for RFA IP 11 014 Funding Number: RFA IP 11 014 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| Campus Suicide Prevention Grants Apply for SM 11 002 Funding Number: SM 11 002 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $102,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DD 11 006", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.